Swing Trader Downtrend Protection v.2 - Generating 7.47% for ZOM
Capitalizing on the Swing: How Downtrend Protection v.2 (TA) Delivered 7.47% Returns for ZOM Amidst Pharmaceuticals' Varied Market Cap
In a dynamic space, the pharmaceutical industry is teeming with companies of varied sizes, capabilities, and financial magnitudes. The average market capitalization across the Pharmaceuticals sector stands at a formidable $2.3 billion, reflecting the robust financial backing of most entities in this area. However, the spread within the group is notably vast, ranging from a modest $246 million to a whopping $77.8 billion.
The pharmaceutical giant Zoetis Inc. (ZTS) stands at the pinnacle of this range, boasting the highest market capitalization at $77.8 billion. The smallest market cap within this group belongs to PEMTF, with a comparatively meager valuation of $246 million.
However, amidst this variegated financial landscape, Zomedica Corp. (ZOM) has carved out a niche for itself. The company recently experienced a notable surge in its returns, thanks to the strategic implementation of the Downtrend Protection v.2 (TA) trading technique, better known as the Swing trading method.
For the uninitiated, Swing trading involves taking advantage of the natural oscillation of stock prices, capitalizing on the upswing, and protecting capital during downturns. This approach offers opportunities for higher returns and risk management, especially in volatile markets.
Zomedica, by adopting the Downtrend Protection v.2 (TA), managed to generate a commendable 7.47% return, a testament to the efficacy of this trading approach. This strategy, designed to shield investments during periods of market volatility, appears to have worked in favor of ZOM.
The use of this technical analysis tool showcases ZOM's ability to strategize its moves amidst a volatile and diverse market environment, thereby optimizing returns for its investors. It is worth noting that the swing trading strategy employed is not about getting the highest possible peak, but about gaining consistent returns. This underlines ZOM's prudent investment approach.
In conclusion, Zomedica's case demonstrates that market capitalization, while important, is not the sole determinant of success in the pharmaceutical industry. Strategic trading mechanisms like Downtrend Protection v.2 (TA) can help companies optimize their returns, even in the face of volatile market conditions and varied capitalizations.
ZOM in +2.84% Uptrend, advancing for three consecutive days on October 28, 2024
Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where ZOM advanced for three days, in of 229 cases, the price rose further within the following month. The odds of a continued upward trend are .
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 12 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
The Aroon Indicator entered an Uptrend today. In of 85 cases where ZOM Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 10, 2024. You may want to consider selling the stock, shorting the stock, or exploring put options on ZOM as a result. In of 84 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
The Moving Average Convergence Divergence Histogram (MACD) for ZOM turned negative on October 14, 2024. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 43 similar instances when the indicator turned negative. In of the 43 cases the stock turned lower in the days that followed. This puts the odds of success at .
ZOM moved below its 50-day moving average on October 07, 2024 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ZOM declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
ZOM broke above its upper Bollinger Band on October 04, 2024. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.526) is normal, around the industry mean (22.821). P/E Ratio (0.000) is within average values for comparable stocks, (83.945). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (5.667). Dividend Yield (0.000) settles around the average of (0.018) among similar stocks. P/S Ratio (5.714) is also within normal values, averaging (42.898).
The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. ZOM’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ZOM’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 87, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
General Information
a company that develops medication for animals
Industry MedicalSpecialties